Onconetix (ONCO) Change in Account Payables (2021 - 2026)
Onconetix (ONCO) posted quarterly Change in Account Payables of -$224779.0 for Q1 2026, up 14.0% year-over-year from -$197179.6 in Q1 2025, and down 392.0% quarter-over-quarter from -$45687.0 in Q4 2025.
Onconetix (ONCO) Change in Account Payables (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Change in Account Payables for 6 consecutive years, with -$224779.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 14.0% year-over-year to -$224779.0; the TTM figure through Mar 2026 stood at -$1.1 million (down 46.61% YoY), while the FY2025 annual figure was -$1.1 million, up 25.96% from the prior year.
- Change in Account Payables slipped to -$224779.0 in Q1 2026 per ONCO's latest filing, from -$45687.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.0 million in Q4 2023 and bottomed at -$1.2 million in Q1 2023.
- Historically, Change in Account Payables has averaged $98297.2 across 5 years, with a median of -$45687.0 in 2025.
- On a YoY basis, Change in Account Payables climbed as much as 1089.69% in 2023 and fell as far as 451.74% in 2023.
- Onconetix's Change in Account Payables stood at $732810.0 in 2022, then soared by 166.73% to $2.0 million in 2023, then tumbled by 112.02% to -$235004.0 in 2024, then soared by 80.56% to -$45687.0 in 2025, then slumped by 392.0% to -$224779.0 in 2026.
- Business Quant data shows ONCO's Change in Account Payables at -$224779.0 in Q1 2026, -$45687.0 in Q4 2025, and -$775167.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 312,116.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 312,116.00 |
| Jun 30, 2026 | 312,116.00 |
| Mar 31, 2026 | -224,779.00 |
| Mar 31, 2026 | -224,779.00 |
| Dec 31, 2025 | -45,687.00 |
| Dec 31, 2025 | -45,687.00 |
| Sep 30, 2025 | -775,167.00 |
| Sep 30, 2025 | -775,167.00 |
| Jun 30, 2025 | -11,439.00 |
| Jun 30, 2025 | -11,439.00 |
| Mar 31, 2025 | -261,362.00 |
| Mar 31, 2025 | -261,362.00 |
| Dec 31, 2024 | -235,004.00 |
| Dec 31, 2024 | -235,004.00 |
| Sep 30, 2024 | 946,558.00 |
| Sep 30, 2024 | 946,558.00 |
| Jun 30, 2024 | -1.17 Mn |
| Jun 30, 2024 | -1.17 Mn |
| Mar 31, 2024 | -1.02 Mn |
| Mar 31, 2024 | -1.02 Mn |